megestrol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   26 Trials   26 Trials   791 News 


«12345678910»
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Clinical, Journal:  Megestrol for Palliative Care in Patients with Cancer. (Pubmed Central) -  May 1, 2020   
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 No abstract available
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    A systematic review of fertility outcomes after uterine preserving management for endometrial cancer and hyperplasia (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_2523;    
    In total, 1,852 patients underwent fertility-sparing treatment in the form of oral medroxyprogesterone acetate (MPA) or megestrol acetate (MA), via the levonorgestrel intrauterine system (LNG-IUS), intramuscular GnRH agonist, and aromatase inhibitors (AI)... Our review of the available evidence suggests that the pregnancy outcomes of fertility-sparing treatment for EAC and AH are favorable.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    A systematic review of fertility outcomes after uterine preserving management for endometrial cancer and hyperplasia (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_1891;    
    In total, 1,852 patients underwent fertility-sparing treatment in the form of oral medroxyprogesterone acetate (MPA) or megestrol acetate (MA), via the levonorgestrel intrauterine system (LNG-IUS), intramuscular GnRH agonist, and aromatase inhibitors (AI)... Our review of the available evidence suggests that the pregnancy outcomes of fertility-sparing treatment for EAC and AH are favorable.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    A systematic review of fertility outcomes after uterine preserving management for endometrial cancer and hyperplasia (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_1234;    
    In total, 1,852 patients underwent fertility-sparing treatment in the form of oral medroxyprogesterone acetate (MPA) or megestrol acetate (MA), via the levonorgestrel intrauterine system (LNG-IUS), intramuscular GnRH agonist, and aromatase inhibitors (AI)... Our review of the available evidence suggests that the pregnancy outcomes of fertility-sparing treatment for EAC and AH are favorable.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    A systematic review of fertility outcomes after uterine preserving management for endometrial cancer and hyperplasia (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_599;    
    In total, 1,852 patients underwent fertility-sparing treatment in the form of oral medroxyprogesterone acetate (MPA) or megestrol acetate (MA), via the levonorgestrel intrauterine system (LNG-IUS), intramuscular GnRH agonist, and aromatase inhibitors (AI)... Our review of the available evidence suggests that the pregnancy outcomes of fertility-sparing treatment for EAC and AH are favorable.
  • ||||||||||  dronabinol oral / Generic mfg.
    Clinical, Journal:  Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting. (Pubmed Central) -  Mar 2, 2020   
    Conclusion and Relevance: In inpatients, there was no difference in change in meal intake or weight between dronabinol, megestrol, or mirtazapine, but they may show numerical improvements in meal intake. To our knowledge, this is the first study to evaluate the use of dronabinol, megestrol, and mirtazapine initiated in the inpatient setting.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Clinical, Journal, HEOR:  The effects of megestrol acetate on nutrition, inflammation and quality of life in elderly haemodialysis patients. (Pubmed Central) -  Mar 2, 2020   
    To our knowledge, this is the first study to evaluate the use of dronabinol, megestrol, and mirtazapine initiated in the inpatient setting. Our data suggest that MA can be effective in improving nutritional status and quality of life by increasing appetite in elderly haemodialysis patients with acceptable side effects; however, MA might not ameliorate inflammation.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer (Henry B. Gonzalez Convention Center - Tower View Registration) -  Feb 17, 2020 - Abstract #ONS2020ONS_661;    
    SYNTHESIS: Pharmacologic interventions (e.g., cyproterone, medroxyprogesterone, megestrol acetate) showed some promise for reducing hot flashes but were associated with side effects and risks...IMPLICATIONS FOR RESEARCH: Evidence is insufficient to support interventions for ADTassociated hot flashes in men with prostate cancer. Future RCTs should be sufficiently powered, include a control group, and use standardized outcome measures.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Megestrol Acetate for Bodybuilding Resulting in Abrupt Hypothalamic-Pituitary Dysfunction (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_2355;    
    Limited data exists in young patients such as ours given limited indications for the agent's use. Importantly, MA should be prescribed with understanding that weight gain is predominantly adipose rather than muscle mass and that its safety is limited by potential HP axis dysfunction, namely adrenal and gonadal deficiencies.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., megestrol / Generic mfg.
    Enrollment open:  Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine (clinicaltrials.gov) -  Jan 13, 2020   
    P4,  N=164, Recruiting, 
    Importantly, MA should be prescribed with understanding that weight gain is predominantly adipose rather than muscle mass and that its safety is limited by potential HP axis dysfunction, namely adrenal and gonadal deficiencies. Not yet recruiting --> Recruiting
  • ||||||||||  dronabinol oral / generics
    Clinical, Journal:  Taste disorders following cancer treatment: report of a case series. (Pubmed Central) -  Nov 24, 2019   
    Treatment trials with current interventions for dysgeusia appeared effective and should be considered in cancer survivors. Understanding taste and flavor function during and following cancer treatment is important in developing rational prospective preventive and interventional strategies.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Nov 15, 2019   
    P2,  N=3, Active, not recruiting, 
    Understanding taste and flavor function during and following cancer treatment is important in developing rational prospective preventive and interventional strategies. Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2019 --> Nov 2020
  • ||||||||||  bepecin (BPC-157) / PLIVA
    Journal:  BPC157 as potential agent rescuing from cancer cachexia. (Pubmed Central) -  Oct 18, 2019   
    In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Oncologic and pregnancy outcomes with fertility-sparing management for early endometrial cancer in young women () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1081;    
    All of the patients were treated with medroxyprogesterone acetate (MPA) or megestrol acetate (MA) or combined MPA/levonorgestrel-intrauterine system (LNG-IUS)...Conclusion Fertility-sparing management for early endometrial cancer with progestin is significantly effective. Patients with maintenance treatment, ART utilization, and without myometrial invasion associated with a higher probability of long-term success.
  • ||||||||||  paclitaxel / Generic Mfg.
    Brain metastases from endometrial cancer: a case report () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1069;    
    The patient died in November 2016, 29 months after brain spread. Conclusion Patients with EC that present with neurologic signs and symptoms should be evaluated for brain metastases because early diagnosis and promptly multimodal treatment can improve the prognosis of these patients.
  • ||||||||||  letrozole / Generic mfg., Megace (megestrol) / BMS, SOBI
    ESR1 HOTSPOT MUTATIONS IN ENDOMETRIAL STROMAL SACROMAS MAY CONFER HORMONAL RESISTANCE (E-Poster Area (Americas)) -  Sep 10, 2019 - Abstract #IGCS2019IGCS_148;    
    Results Both patients received at least two lines of hormonal suppressive therapy including letrozole and megestrol. Our findings suggest that the ESR1 Y537S hotspot mutation in LGESS, either pre-existing or acquired, may be associated with endocrine resistance and/or high-grade transformation in these lesions.
  • ||||||||||  phenytoin / Generic mfg., megestrol / Generic mfg.
    Phase classification:  Phenytoin for Memory Impairment Secondary to Megestrol (clinicaltrials.gov) -  Sep 9, 2019   
    P4,  N=21, Completed, 
    MA/metformin may lead to a higher CR rate, shorter treatment time and less weight gain compared with MA alone. Phase classification: P1 --> P4
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Megace (megestrol) / BMS, SOBI
    Clinical, Journal:  Upper Gastrointestinal Bleeding in a Male Patient Taking Megestrol Acetate and Rivaroxaban: A Case Report. (Pubmed Central) -  Sep 7, 2019   
    MGA, a synthetic derivative of endogenous progesterone used to treat GFTT, may exert either prothrombotic or anticoagulant effects, and as such potential for drug interactions with anticoagulants must be considered. Patients taking MGA should be closely monitored for coagulation changes throughout transitions of care.
  • ||||||||||  Duphaston (dydrogesterone) / Abbott
    Journal:  Occurrence and removal of progestagens in municipal wastewater treatment plants from different regions in China. (Pubmed Central) -  Jul 26, 2019   
    Specially, the behaviors of progestagens along the anaerobic-anoxic-oxic of a WWTP were further explored and the aerobic tank is the main contributor to the removal of progestagens. Finally, in the effluent of these 21 WWTPs, daily mass loadings of the total progestagens ranged from 0.51 to 10.4 g d. Notably, LNG exhibited high potential risk to the fish base on risk quotient.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Review, Journal:  Megestrol acetate for cachexia-anorexia syndrome. A systematic review. (Pubmed Central) -  Jul 17, 2019   
    MA vs. active drugs: MA patients gained weight (MD 2.5 kg, 95% CI [0.37, 4.64]) but did not gain QOL (MD 0.20 95% CI [-0.02, 0.43]) and did not report an increase in adverse events (RR 1.05 95% CI [0.95, 1.16]) or in deaths (RR 1.53, 95% CI [1.02, 2.29]) Different doses of MA: in studies where lower doses of MA were compared with higher doses of MA, we did not find differences either in weight gain (MD -0.94 kg, 95% CI [-3.33, 1.45]), QOL (MD 0.31 95% CI [-0.19, 0.81]), or adverse events (RR 1.34, 95% CI [0.65, 2.76]). Thus, we cannot reach a conclusion for an optimal dose of MA.
  • ||||||||||  dronabinol oral / generics
    Retrospective data, Review, Journal:  Systematic review and meta-analysis of cannabinoids in palliative medicine. (Pubmed Central) -  Jul 11, 2019   
    In another study comparing megestrol to dronabinol in HIV patients, megestrol treatment led to higher weight gain without any differences in tolerability and safety. We found no convincing, unbiased, high quality evidence suggesting that cannabinoids are of value for anorexia or cachexia in cancer or HIV patients.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Clinical, Review, Journal:  Thromboprophylaxis in cancer patients in hospice. (Pubmed Central) -  Jul 1, 2019   
    ...Hospice patients are frequently given medications increasing VTE risk, for instance megestrol which is a drug commonly used in cancer cachexia...So far, most of the guidelines issued by oncological societies do not precisely refer to the problem of TPX in hospice patients. Therefore, the decisions on the implementation of anticoagulation should be taken individually, with previous assessment of VTE risk, comorbidities and possible hemorrhagic complications.
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Clinical, Journal:  Lowered Fasting Blood Glucose (FBG) in a Prediabetic Individual with HIV Despite Struggle with Weight Control Management- CASE STUDY (FS17-06-19). (Pubmed Central) -  Jun 23, 2019   
    ...When questioned about the weight gain, PB revealed that he had started taking an appetite stimulant (Megace) to address the wasting on his periphery, claiming that he looked "sickly"...This improvement in FBG levels suggests that despite the difficulty of effective weight management in these patients, proper glucose values may still be achieved with nutrition counseling and education, thus lowering risk for diabetes and associated complications. NIGMS-RISE funding, National Institute on Drug Abuse 5U01DA040381-03 and FIU-Dissertation Funding.